Risk factors
Polaryx Therapeutics (PLYX) risk factors
Item 1A of every Polaryx Therapeutics, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors63 risks
Clinical stage biotech with accumulated deficit of $99.6 million dependent on PLX-200 and PLX-300. Programs focus on rare pediatric lysosomal storage disorders facing intense competition. Substantial doubt about ability to continue as a going concern.
Filed Mar 24, 2026